KDR and hypertensive disorder: Because anti-VEGFR TKI therapies can lead to the new onset or worsening of established hypertension, all patients should have optimal blood pressure (BP) (<140/90 mmHg) control before the initiation of treatment and maintain a controlled BP (<140/90 mmHg, or lower in the case of overt proteinuria) throughout treatment.